Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P11166
UPID:
GTR1_HUMAN
Alternative names:
Glucose transporter type 1, erythrocyte/brain; HepG2 glucose transporter
Alternative UPACC:
P11166; A8K9S6; B2R620; D3DPX0; O75535; Q0P512; Q147X2
Background:
Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1), also known as Glucose transporter type 1, plays a pivotal role in glucose uptake. It is essential for basal glucose transport across the blood-brain barrier, ensuring the brain's energy supply. SLC2A1's broad substrate specificity allows it to transport various aldoses, highlighting its critical function in energy metabolism.
Therapeutic significance:
SLC2A1's dysfunction is linked to several neurological disorders, including GLUT1 deficiency syndrome 1 and 2, Epilepsy, idiopathic generalized 12, Dystonia 9, and Stomatin-deficient cryohydrocytosis with neurologic defects. These associations underscore the protein's potential as a target for therapeutic intervention in a range of neurologic conditions.